Nephrocare Health Services IPO is fully book build issue and total IPO size is ₹35.3405 crores. The entire share offering is a fresh issue worth ₹35.3405 crores.
The dates for the Nephrocare Health Services IPO have not been announced yet. The allotment process is expected to be finalized by [.].
The Nephrocare Health Services IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Nephrocare Health Services IPO has not been announced yet.
Registrar for this IPO is Kfin Technologies Limited and lead managers for Nephrocare Health Services IPO are Icici Securities Limited, Ambit Private Limited, Iifl Capital Services Limited, Nomura Financial Advisory And Securities (India) Private Limited.
IPO Schedule
| IPO Open Date | - |
|---|---|
| IPO Close Date | - |
| IPO Allotment Date | - |
| Refund Initiation | - |
| Share credit in Demat | - |
| Listing Date | - |
Key Details
| Price Band | TBA |
|---|---|
| Lot Size | TBA |
| Face Value | ₹2 Per Equity Share |
| Total Issue Size | 12,792,056 Shares + ₹35 Crores |
| Fresh Issue | ₹35.34 Crores |
| OFS Issue | 12,792,056 Shares |
| Issue Type | Fresh Issue and Offer for Sale |
| Listing At | BSE, NSE |
Share Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | 50% |
| Retail | 35% |
| NII/HNI | 15% |
About Nephrocare Health Services Limited Company
Nephrocare Health Services (NephroPlus) is India's largest dialysis service provider, with 490 clinics including 43 internationally in Philippines, Uzbekistan, and Nepal. They serve 33,076 patients and performed 3.3 million treatments in Fiscal Year 2025. A key focus is accessibility, especially in Tier II and Tier III cities, where 76.73% of their clinics are located.
Their operating philosophy centers on accessibility, quality, and value. They operate through various models, including in-hospital clinics and public-private partnerships. Revenue from operations stood at ₹755.81 crore with a PAT of ₹67.1 crore. EBITDA (excluding other income) margin was at 22.05%, and RoCE was 18.67%. The company demonstrates a strong CFO/EBITDA ratio of 81.22%. Revenue contribution from outside India stood at 31.79%.
NephroPlus's commitment extends to providing holiday dialysis and dialysis on call and wheels, enhancing patient convenience and access.
Nephrocare Health Services Limited Financial Details
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 996.46 | 806.02 | 666.23 |
| Revenue | 755.81 | 566.16 | 437.30 |
| Profit After Tax | 67.10 | 35.13 | -11.79 |
| Net Worth | 584.11 | 413.71 | 388.63 |
| Reserves and Surplus | 578.68 | 408.57 | 383.50 |
| Total Borrowing | 225.80 | 243.37 | 196.21 |
₹ In Crore
Key Performance Indicator
| Basic EPS (in ₹) | Return on Net Worth (RoNW) | Net Asset Value (NAV) | Debt-Equity Ratio | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|---|---|---|---|---|
| 8.28 | 13.19% | 59.56 |
Offer Objectives
The Offer comprises a fresh issue of equity shares aggregating up to ₹35.34 crore by the company and an Offer for Sale (OFS) of 12,792,056 equity shares by the selling shareholders. The company will not receive any proceeds from the OFS.
Selling Shareholders: The OFS includes shares from IPEF II (up to 1,660,360 shares), HPL (up to 1,813,140 shares), IGOF (up to 147,765 shares), Edoras Investment Holdings Pte. Ltd. (up to 4,081,000 shares), IIPEOL (up to 121,985 shares), IFC (up to 3,089,663 shares), 360 One Series 9 (up to 1,433,468 shares), and 360 One Series 10 (up to 444,675 shares).
Fresh Issue Net Proceeds: The gross proceeds from the fresh issue are estimated at ₹35.34 crore. These proceeds will be utilized as follows:
1. Capital expenditure for opening new dialysis clinics in India: ₹12.91 crore.
2. Pre-payment or scheduled repayment of certain borrowings: ₹13.60 crore.
3. General corporate purposes.
The deployment of the net proceeds is scheduled over Fiscal Years 2026, 2027, and 2028.
Company Details
Address:
5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad 500 081, Telangana, India
Phone: +91 40 4240 8039
Email: [email protected]
Website: http://www.nephroplus.com
IPO Registrar Details
KFin Technologies Limited
Phone: +91 40 6716 2222
Email: [email protected]
Website: http://www.kfintech.com
Offer Prospectus & Documents
Lead Managers
- Icici Securities Limited
- Ambit Private Limited
- Iifl Capital Services Limited
- Nomura Financial Advisory and Securities (India) Private Limited
